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given that HELP represents a last therapeutic option for these
patients. The annual budget impact was $1.0 and $61.0 million
(CAD) for HMZ and HTZ FH patients respectively. Costs were
halved with biweekly treatment. The cost per CHD death
avoided comparing HELP with Plasma Exchange (PE), current
treatment, and with no intervention in HTZ FH was estimated to
be $37.5 million and $18.7 million for weekly and biweekly
treatment respectively. Although HELP costs twice as much as
PE, it avoided 12 deaths versus PE and 22 deaths versus no
intervention over a 10-year period. CONCLUSION: There is
evidence of overall clinical beneﬁt of LDL apheresis for HMZ
and HTZ FH. The diffusion of LDL apheresis for refractory HTZ
FH should factor affordability and potential capital and human
resource constraints.
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OBJECTIVE: Point-of-Care (POC) devices that measure the
International Normalized Ratio (INR) may be associated with
enough measurement error to inﬂuence warfarin dosing deci-
sions. The purpose of this trial was to determine if there were
differences between any of ﬁve FDA-approved POC testing
devices in terms of the proportion of time patients spend in the
target INR range (TR). METHODS: In this longitudinal clinical
trial, patients were randomized to one of ﬁve POC devices that
measure the INR (International Normalized Ratio). Patients
were followed over time according to usual anticoagulation clinic
practice. Clinicians used measurements from the POC device to
make all clinical decisions, including warfarin dose changes. At
each visit, a venous blood sample was also collected to serve as
an accepted standard measure to calculate time in the target
range (TR). A Bayesian hierarchical model with a parametric
variance component for estimating coagulation times between
observed blood draws was used to estimate the mean proportion
of time each patient’s INR was within his or her TR. The analysis
assessed the probability that each device resulted in patients’ INR
values within the TR over time, as measured by the accepted
standard laboratory measure. RESULTS: A total of 287 patients
were enrolled, completed 3 visits, and were monitored for an
average of 87 days. There was signiﬁcant differences in the time
patients’ INR values were in the target range, based on POC
device: Coaguchek S (52.2%), Coaguchek ProDM (51.5%)
Hemochron Jr. (48.3%), ProTime (45.5%), and Rapidpoint
(41.2%). The posterior probabilities that the Coaguchek S and
Coaguchek ProDM were the superior devices were 0.58 and
0.31, respectively. CONCLUSION: Five FDA-approved POC
INR devices resulted in signiﬁcantly different time in the TR. This
suggests that there are clinically signiﬁcant differences amongst
FDA-approved devices. Measurement of clinical outcomes may
improve the regulatory approval process.
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OBJECTIVE: Evaluate treatment patterns and levels of blood
pressure (BP) and glycemic control in elderly patients with
comorbid hypertension and type 2 diabetes. METHODS: Retro-
spective review of 2 consecutive years (August 1, 2005–July 31,
2007) of medical claims, pharmacy claims, and medical charts
from a physician group, comprised of more than 200 physicians,
located in the Ohio Valley region. Patients 65 years-of-age and
older with an ICD-9 diagnosis code for both hypertension and
type 2 diabetes were identiﬁed for inclusion between August 1,
2005–July 31, 2006, and evaluated from August 1, 2006–July
31, 2007. Administrative claims databases were utilized to
analyze treatment patterns. Medical charts was reviewed to
conﬁrm diagnoses and collect clinical indicators of control,
including BP and hemoglobin A1C measurements. RESULTS:
This study included 505 patients with hypertension and type 2
diabetes. The mean age was 75.7 years, and 57% were females.
Approximately 35% (n = 177) achieved BP goal of <130/
80 mmHg, while 58% (n = 293) achieved glycemic control,
deﬁned as A1C <7%. Only 26% (n = 133) attained both goal BP
and A1C levels. The most prescribed antihypertensive and anti-
hyperglycemic classes were beta-blockers (50%) and sulfony-
lureas (44%), respectively. Forty-seven percent of the patients
were on an angiotensin converting enzyme inhibitor, and 14%
were on an angiotensin receptor blocker. Antihypertensive mono-
therapy was the least prevalent (21%) mode of therapy, followed
by therapy with two agents (29%), and >3 agents (50%). In
contrast, antthyperglycemic monotherapy was the most preva-
lent (55%) mode of therapy, followed by dual therapy (30%),
and >3 agents (15%). CONCLUSION: Elderly patients with
comorbid hypertension and type 2 diabetes did not achieve goal
BP, and over 40% did not achieve goal A1C. Further opportu-
nities to educate both health care providers and patients are
necessary in order to prevent complications associated with the
poor management of these two common conditions.
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OBJECTIVE: To explore variation in practice and its impact on
QoL in management of acute coronary syndromes (ACS), the
commonest cardiac cause of hospital admission. METHODS: A
prospective, international, observational study recruited ACS
patients undergoing percutaneous coronary intervention (PCI),
January–August 2007, capturing practice patterns, resource use
and QoL. RESULTS: A total of 1525 ACS-PCI patients (Spain-
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